Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Skeletal Radiology
Published in: Skeletal Radiology 4/2017

01-04-2017 | Scientific Article

Characterisation of musculoskeletal tumours by multivoxel proton MR spectroscopy

Authors: Ruchi S. Patni, Deb K. Boruah, Shantiranjan Sanyal, Bidyut B. Gogoi, Maninder Patni, Rosy Khandelia, Nripen Gogoi

Published in: Skeletal Radiology | Issue 4/2017

Login to get access

Abstract

Objective

The purpose of this study is to evaluate the role of multi-voxel proton MR spectroscopy in differentiating benign and malignant musculoskeletal tumours in a more objective way and to correlate the MRS data parameters with histopathology.

Methods and materials

A hospital-based prospective study was carried out comprising 42 patients who underwent MRI examinations from 1 July 2013 to 30 June 2014. After routine sequences, single-slice multi-voxel proton MR spectroscopy was included at TE-135 using the PRESS sequence. The voxel with the maximum choline/Cr ratio was used for analysis of data in 32 patients. The strength of association between the MR spectroscopy findings and the nature of tumour and histopathological grading were assessed.

Results

Of the 42 patients, the MR spectra were not of diagnostic quality in 10. In the remaining 32 patients, 12 (37.5%) had benign and 20 (62.5%) malignant tumours. The mean choline/Cr ratio was 6.97 ± 5.95 (SD) for benign tumours and 25.39 ± 17.72 (SD) for malignant tumours. In our study statistical significance was noted between the choline/Cr ratio and the histological nature of musculoskeletal tumours (p = 0.002) assessed by unpaired t-test. The choline/Cr ratio and histological grading were also found to be significant (p = 0.001) when assessed by one-way ANOVA test.

Conclusions

Multi-voxel MR spectroscopy showed a higher choline/Cr ratio in malignant musculoskeletal tumours than in benign ones (p = 0.002). The choline/Cr ratio and histological grading of musculoskeletal tumours also showed statistical significance (p = 0.001).
Literature
1.
Stark DD, Bradley WG. Magnetic Resonance Imaging, 2nd ed. St. Louis Mosby-Year Book 1992.
2.
Wang CK, Hsieh TJ, Jaw TS, Lin JN, Liu GC, Li CW. Clinical application of in vivo proton (1H) MR spectroscopy. Spectroscopy. 2005;19:181–90.CrossRef
3.
Rosenberg AE. Chapter 26- Bones, Joints, and Soft Tissue Tumours, Kumar V, Abbas AK, and Fausto N, Robbin and Cotran Pathologic Basis of Disease, 7th edition, Elsevier Inc. India; 2004:1273-1324.
4.
Daniel Jr A, Ullah E, Wahab S, Kumar Jr V. Relevance of MRI in prediction of malignancy of musculoskeletal system—A prospective evaluation. BMC Musculoskelet Disord. 2009;10:125.CrossRefPubMed
5.
Hermann G, Abdel Wahab IF, Miller TT, Klein MJ, Lewis MM. Tumour and tumour-like conditions of the soft tissue: magnetic resonance imaging features differentiating benign from malignant masses. Br J Radiol. 1992;65(769):14–20.CrossRefPubMed
6.
Alyas F, James SL, Davies AM, Saifuddin A. The role of MR imaging in the diagnostic characterisation of appendicular bone tumours and tumour-like conditions. Eur Radiol. 2007;17(10):2675–86.CrossRefPubMed
7.
Sah PL, Sharma R, Kandpal H, Seith A, Rastogi S, Bandhu S, et al. In vivo proton spectroscopy of giant cell tumor of the bone. Am J Roentgenol. 2008;190:433.CrossRef
8.
Van der Graaf M. In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J. 2010;39:527–40.CrossRefPubMed
9.
Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 2004;232:599–605.CrossRefPubMed
10.
Subhawong TK, Wang X, Durand DJ, Jacobs MA, Carrino JA, Machado AJ, et al. Proton MR spectroscopy in metabolic assessment of musculoskeletal lesions. Am J Roentgenol. 2012;198:162–72.CrossRef
11.
Fayad LM, Wang X, Salibi N, Barker PB, Jacobs MA, Machado AJ, et al. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. Am J Roentgenol. 2010;195:207.CrossRef
12.
Marks KE, Belhobek GH. Chapter 10. Tumours of the Musculoskeletal System. Robert B Duthie & George Bently. Mercer’s Orthopaedic Surgery, 9th ed. Jaypee Brothers. India, 2003;653-676.
13.
Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devessa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30.CrossRefPubMed
14.
Murphey MD, Nomikos GC, Flemming DJ, Gan-non FH, Temple HT, Kransdorf MJ. From the Archives of the AFIP: Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. RadioGraphics. 2001;21(5):1283–309.CrossRefPubMed
15.
Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003;24:1989–98.PubMed
16.
Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology. 2006;239:686–92.CrossRefPubMed
17.
18.
Mountford C, Lean C, Malycha P, Russell P. Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging. 2006;24:459–77.CrossRefPubMed
19.
Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem. 2003;90:525–33.CrossRefPubMed
20.
Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992;5:226–33.CrossRefPubMed
21.
Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–14.CrossRefPubMed
22.
Mullins ME. MR spectroscopy: truly molecular imaging—past, present and future. Neuroimaging Clin N Am. 2006;16:605–18.CrossRefPubMed
23.
Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in-vivo 1H MR spectroscopy—a pilot study at 4T. Radiology. 2004;233:424–31.CrossRefPubMed
24.
Krouwer HG, Kim TA, Rand SD, Prost RW, Haughton VM, Ho KC, et al. Singlevoxel proton MR spectroscopy of non neoplastic brain lesions suggestive of a neoplasm. Am J Neuroradiol. 1998;19:1695–703.PubMed
25.
Venkatesh SK, Gupta RK, Pal L, Husain N, Husain M. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging. 2001;14:8–15.CrossRefPubMed
26.
Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging. 2006;23(1):23–8.CrossRefPubMed
27.
Maheshwari SR, Mukherji SK, Neelon B, Schiro S, Fatterpekar GM, Stone JA, et al. The choline/creatine ratio in five benign neoplasms: comparison with squamous cell carcinoma by use of in-vitro MR spectroscopy. Am J Neuroradiol. 2000;21(10):1930–5.PubMed
28.
Fayad LM, Barker PB, Jacobs MA, Eng J, Weber KL, Kulesza P, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. Am J Roentgenol. 2007;188:1513–20.CrossRef
29.
Lee CW, Lee JH, Kim DH, Min HS, Park BK, Cho HS, et al. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification. Clin Imaging. 2010;34:47–52.CrossRefPubMed
30.
Costa FM, Vianna EM, Domingues RC, Setti M, Meohas W, Rezende JF, et al. Proton magnetic resonance spectroscopy and perfusion magnetic resonance imaging in the evaluation of musculoskeletal tumors. Radiol Bras. 2009;42(4):215–23.CrossRef
31.
Russo F, Mazzetti S, Grignani G, De Rosa G, Aglietta M, Anselmetti GC, et al. In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. Eur Radiol. 2012;22:1131–9.CrossRefPubMed
32.
Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol. 2007;11(3):240–5.CrossRefPubMed
Metadata
Title
Characterisation of musculoskeletal tumours by multivoxel proton MR spectroscopy
Authors
Ruchi S. Patni
Deb K. Boruah
Shantiranjan Sanyal
Bidyut B. Gogoi
Maninder Patni
Rosy Khandelia
Nripen Gogoi
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Skeletal Radiology / Issue 4/2017
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-017-2573-1

Other articles of this Issue 4/2017

Skeletal Radiology 4/2017 Go to the issue

Meeting Review

The Annual Scientific Meeting of the European Society of Musculoskeletal Radiology (ESSR) 2016 in Zurich, Switzerland: summary

Browser's Notes

Browser's Notes

Scientific Article

Association of core needle biopsy tract resection with local recurrence in extremity soft tissue sarcoma

Scientific Article

Degeneration of articular cartilage in osteonecrosis of the femoral head begins at the necrotic region after collapse: a preliminary study using T1 rho MRI

Technical Report

CT-guided percutaneous screw fixation plus cementoplasty in the treatment of painful bone metastases with fractures or a high risk of pathological fracture

Review Article

Ultrasound evaluation of bursae: anatomy and pathological appearances